Neogenomics IncNEO
Price$17.78

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $766.3M+16.0% YoYTTM through 30 Jun 2026
Net Income -$51.9MTTM through 30 Jun 2026
Free Cash Flow -$7.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin43.3%
EBITDA Margin-5.6%
Operating Margin-9.7%
Net Margin-6.8%

Returns

-119.6%ROE
-7.4%ROA

Balance Sheet Health

Debt / Equity4.13x
Current Ratio3.60x
Net Debt$196.1M
Cash & Equivalents$145.5M

Quality Metrics

Altman Z-Score2.75
Piotroski F-Score4 / 9
FCF Margin-1.0%
Rule of 404.0
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $727.3M
Diluted EPS
'19'20'21'22'23'24'25
FY2025: $-0.84

Dividend

No dividend

Capital Allocation

R&D Spend$38.2M
Capex Intensity3.8%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.